A kind of anti-interference troponin I immunofluorescence test strip
By using a double sandwich method of labeled antibodies in cardiac troponin detection, the problem of strong interference in the detection was solved, and a more accurate and stable cardiac troponin I detection results were achieved.
Patent Information
- Application Number
- CN202411027461.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-07-30
AI Technical Summary
There are strong interference problems in the existing cardiac troponin detection methods, resulting in false negative and false positive results, affecting the accuracy of clinical diagnosis.
Two different troponin antibodies are used to mix them in a certain proportion to prepare anti-interference troponin I immunofluorescent test strips, which are detected by fluorescent immunochromatography technology to reduce interference and improve detection accuracy.
It effectively reduces false positives and false negatives of the test results, improves the accuracy and stability of the test results, and simplifies the detection process.
Smart Images

Figure CN118549659B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of in vitro diagnostic reagents, and in particular to an anti-interference troponin I immunofluorescence test strip. Background Art
[0002] Due to its strong specificity, sensitivity and wide diagnostic window, cardiac troponin has become the most specific and sensitive marker of myocardial injury in recent years and is widely used in clinical practice. The cardiac troponin complex is composed of three subunits, C, T and I, and plays an important regulatory role in the contraction of myofibrils in skeletal muscle cells. The troponin content in normal human blood is extremely low. When myocardial cells are damaged, free troponin is released from myocardial cells into the blood, causing the blood concentration to increase. The cTnI released by myocardial cell damage mainly exists in the form of cTnI and cTnC complex, and free cTnI is less.
[0003] The main detection methods for cardiac troponin at present include enzyme-linked immunosorbent assay, chemiluminescence assay, immunochromatography, etc. The detection results of enzyme-linked immunosorbent assay and chemiluminescence assay are relatively more accurate and more sensitive, but the detection process is relatively cumbersome and costly. Immunochromatography is easy and quick to operate, but it is affected by many interferences, including subjective and objective factors. Subjective factors include factors affecting the preparation of reagent cards used in immunochromatography, such as spraying, strip loading, and shell pressing; objective factors include endogenous interfering substances in blood samples, such as autoantibodies, heterophilic antibodies, and human anti-animal antibodies. Since various interfering factors can lead to false negative and false positive results, which in turn affect the correct clinical judgment and treatment of the disease, it is particularly important to resolve interference in immunoassays. Summary of the invention
[0004] In order to solve the above technical problems, the present invention provides an anti-interference troponin I immunofluorescence test strip, which solves the defect of strong interference in the detection process by means of marking two different troponin antibodies and mixing them in a certain proportion.
[0005] An anti-interference troponin I immunofluorescence test strip comprises an assembled NC reaction membrane and a conjugation pad, wherein the NC reaction membrane comprises a T line and a C line; and a labeled antibody mixture containing two antibodies is coated in the conjugation pad.
[0006] The active ingredient content of the labeled antibody mixture provided by the present invention is 50mM Trisbase buffer, 1% sucrose, 1% bovine serum albumin, 0.5% Tween 20, 0.5% isopropanol, 0.1% sodium azide, 0.1% cTnI labeled microsphere antibody 1, and 0.5% cTnI labeled microsphere antibody 2.
[0007] The active ingredient content of the T line is 50mM phosphate buffer, 1% trehalose, 1% bovine serum albumin, 0.5% Tween 20, 0.1% sodium azide, and 1mg / ml cTnI antibody PcAb;
[0008] The active ingredient content of the C line is 50mM phosphate buffer, 1% trehalose, 1% bovine serum albumin, 0.5% Tween 20, 0.1% sodium azide, and 0.6mg / ml goat anti-mouse polyclonal antibody;
[0009] The conjugate pad contains the labeled antibody mixture described above.
[0010] Preparation method:
[0011] Preparation of NC reaction membrane for Troponin I:
[0012] 1) Weigh the prepared solutions corresponding to the T line and C line respectively;
[0013] The solutions corresponding to the T line and the C line were sprayed respectively and coated onto the NC membrane. After drying for 12 hours, the NC reaction membrane was prepared.
[0014] 2) Preparation of troponin I binding pad: a: Labeling of antibody 1 and antibody 2: After two 200nm fluorescent microspheres were activated by EDC and NHS, they were coupled with cTnI monoclonal antibody 1 (cTnI-3E12 purchased from Huakui Jinpei, catalog number M3063) and cTnI monoclonal antibody 2 (Anti-cTnI purchased from Hytest, catalog number 4T21cc MAb560cc) for 3 hours, and blocked with 10% glycocholic acid for 1 hour to prepare cTnI labeled microsphere antibody 1 and cTnI labeled microsphere antibody 2. b: The labeled antibodies were accurately weighed according to the concentration of the required active ingredients to prepare a labeled antibody mixture, and the mixture was sprayed onto the pre-treated binding pad. After drying for 12 hours, the fluorescent microsphere labeled cTnI monoclonal antibody binding pad was prepared;
[0015] 3) Assembly: On the PVC base plate, the following are overlapped and pasted in sequence: cTnI NC reaction membrane, absorbent paper, fluorescent microsphere-labeled cTnI monoclonal binding pad and sample pad to assemble into a cTnI large plate;
[0016] 4) Card loading: Cut the cTnI large plate into 4 mm small strips and load them into the reagent card. Pass the card through a press to obtain the card.
[0017] The test strip prepared by the present invention is based on the fluorescent immunochromatography technology and adopts the double antibody sandwich method to measure the content of cTnI in human whole blood, plasma, serum and peripheral blood samples. After the sample is added, the cTnI in the sample binds to the fluorescent microsphere-labeled cTnI monoclonal antibody to form a fluorescent microsphere-labeled cTnI monoclonal antibody-test object complex. When the complex moves along the nitrocellulose reaction membrane to the detection zone (T zone) under the action of chromatography, it binds to the cTnI monoclonal antibody coated on the nitrocellulose reaction membrane to form a sandwich complex of fluorescent microsphere-labeled cTnI monoclonal antibody-test object-cTnI monoclonal antibody, while the fluorescent microsphere-labeled cTnI monoclonal antibody that has not formed a complex continues to move forward along the nitrocellulose reaction membrane to the quality control zone (C zone) and binds to the goat anti-mouse polyclonal antibody coated on the nitrocellulose reaction membrane. Under the action of the excitation light source, the fluorescent substance absorbs energy and reaches a high energy level. When it transitions to a low energy level, it releases energy to produce a fluorescent signal of a specific wavelength. The dry fluorescent immunoassay analyzer captures the fluorescent signal and converts it into fluorescence intensity. It calculates the ratio of the fluorescence intensity of the detection band to the fluorescence intensity of the quality control band. Based on the calibration curve, the instrument automatically calculates the concentration of cTnI in the test object.
[0018] The beneficial effects of the present invention are as follows: the cTnI immunofluorescence quantitative test strip of the present invention has strong anti-interference ability, ensures the accuracy of the test result, has good stability, and has a simple detection method, and is worthy of further widespread promotion. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 It is a linear comparison diagram of comparative example 1 and the test value;
[0020] Figure 2 It is a linear comparison diagram of comparative example 2 and the test value;
[0021] Figure 3 It is a linear comparison diagram of comparative example 3 and the test value;
[0022] Figure 4 It is a linear comparison diagram of comparative example 4 and the test value;
[0023] Figure 5 It is a linear comparison diagram of Example 1 and the test value;
[0024] Figure 6 It is a linear comparison diagram of comparative example 5 and the test value;
[0025] Figure 7 It is a linear comparison diagram of comparative example 6 and the test value;
[0026] Figure 8 The cTnI reagent strip prepared in Example 1 and the Roche cTnI kit were used to test 100 plasma samples for comparison. DETAILED DESCRIPTION
[0027] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0028] The instruments involved in the following embodiments of the present invention include: dry type fluorescent immunoassay analyzer AFS2000 produced by Guangzhou Lanbo Biotechnology Co., Ltd.
[0029] Example 1
[0030] Prepare the labeled antibody mixture: 50 mM Trisbase buffer, 1% sucrose, 1% bovine serum albumin, 0.5% Tween 20, 0.5% isopropanol, 0.1% sodium azide, 0.1% cTnI labeled microsphere antibody 1, 0.5% cTnI labeled microsphere antibody 2;
[0031] Prepare T-line solution and C-line solution:
[0032] The active ingredient content of the T line is 50 mM phosphate buffer, 1% trehalose, 1% bovine serum albumin, 0.5% Tween 20, 0.1% sodium azide, and 1 mg / ml cTnI antibody PcAb;
[0033] The active ingredient content of line C is 50mM phosphate buffer, 1% trehalose, 1% bovine serum albumin, 0.5% Tween 20, 0.1% sodium azide, and 0.6mg / ml goat anti-mouse polyclonal antibody.
[0034] The test strips were prepared by the following method:
[0035] 1) Weigh the prepared solutions corresponding to the T line and C line respectively;
[0036] The solutions corresponding to the T line and the C line were sprayed respectively and coated onto the NC membrane. After drying for 12 hours, the NC reaction membrane was prepared.
[0037] 2) Preparation of Troponin I Binding Pad:
[0038] a: Labeling of antibody 1 and antibody 2: Two 200 nm fluorescent microspheres were activated by EDC and NHS, and then coupled with cTnI monoclonal antibody 1 (cTnI-3E12 purchased from Huakui Jinpei, catalog number M3063) and cTnI monoclonal antibody 2 (Anti-cTnI purchased from Hytest, catalog number 4T21cc MAb560cc) for 3 h, respectively, and blocked with 10% glycocholic acid for 1 h, respectively, to prepare cTnI labeled microsphere antibody 1 and cTnI labeled microsphere antibody 2;
[0039] b: Accurately weigh the labeled antibody according to the concentration of the required active ingredient to prepare a labeled antibody mixture, spray the mixture onto the pre-treated binding pad, and after drying for 12 hours, prepare a fluorescent microsphere-labeled cTnI monoclonal antibody binding pad;
[0040] 3) Assembly: On the PVC base plate, the following are overlapped and pasted in sequence: cTnI NC reaction membrane, absorbent paper, fluorescent microsphere-labeled cTnI monoclonal binding pad and sample pad to assemble into a cTnI large plate;
[0041] 4) Card loading: Cut the cTnI plate into 4 mm strips and load them into the reagent card. Pass the card through a press to obtain the card.
[0042] Comparative test
[0043] Test strips were prepared according to the above preparation method, and the effect of the antibody ratio in the mixed solution on the specificity and the long-term stability were evaluated.
[0044] Comparative Example 1
[0045] Labeled antibody mixture: 50 mM Trisbase buffer, 1% sucrose, 1% bovine serum albumin, 0.5% Tween 20, 0.5% isopropanol, 0.1% sodium azide, 0.1% cTnI labeled microsphere antibody 1, and the rest is the same as in Example 1.
[0046] Comparative Example 2
[0047] Labeled antibody mixture: 50 mM Trisbase buffer, 1% sucrose, 1% bovine serum albumin, 0.5% Tween 20, 0.5% isopropanol, 0.1% sodium azide, 0.1% cTnI labeled microsphere antibody 2; other components are the same as in Example 1.
[0048] Comparative Example 3
[0049] Labeled antibody mixture: 50 mM Trisbase buffer, 1% sucrose, 1% bovine serum albumin, 0.5% Tween 20, 0.5% isopropanol, 0.1% sodium azide, 0.1% cTnI labeled microsphere antibody 1, 0.1% cTnI labeled microsphere antibody 2; other components are the same as in Example 1.
[0050] Comparative Example 4
[0051] Labeled antibody mixture: 50 mM Trisbase buffer, 1% sucrose, 1% bovine serum albumin, 0.5% Tween 20, 0.5% isopropanol, 0.1% sodium azide, 0.5% cTnI labeled microsphere antibody 1, 0.1% cTnI labeled microsphere antibody 2; other components are the same as in Example 1.
[0052] Comparative Example 5
[0053] Labeled antibody mixture: 50 mM Trisbase buffer, 1% sucrose, 1% bovine serum albumin, 0.5% Tween 20, 0.5% isopropanol, 0.1% sodium azide, 0.8% cTnI labeled microsphere antibody 1, 0.1% cTnI labeled microsphere antibody 2; other components are the same as in Example 1.
[0054] Comparative Example 6
[0055] Labeled antibody mixture: 50 mM Trisbase buffer, 1% sucrose, 1% bovine serum albumin, 0.5% Tween 20, 0.5% isopropanol, 0.1% sodium azide, 0.1% cTnI labeled microsphere antibody 1, 0.8% cTnI labeled microsphere antibody 2, and the rest is the same as in Example 1.
[0056] Test results:
[0057] (1) Anti-interference
[0058] The binding pads composed of 7 kinds of labeled antibody mixtures were matched with NC reaction membranes to form 7 kinds of troponin immunofluorescence test strips. The cTnI content in the samples was determined mainly by sample comparison analysis, with the existing hospital value of the sample as the horizontal axis and X2 / X1 as the vertical axis, where X1 is the C line reaction intensity, X2 is the T line reaction intensity, X2 / X1 is T / C, and the T / C intensity is correlated with the size of the sample measurement value. The hospital measurement value is the measurement result of Roche Troponin I Assay Kit (chemiluminescence method) on Roche's chemiluminescence instrument. The results were analyzed. The specific results are shown in Tables 1, 2, 3 and 4, and the line graphs are shown in Tables 1, 2, 3 and 4. Figure 1 , Figure 2 , Figure 3 and Figure 4 shown.
[0059] Table 1 Comparative Example 1 Comparative test results of antibody 1 alone
[0060]
[0061] Table 2 Comparative Example 2 Comparison test results of antibody 2 alone
[0062]
[0063] Table 3 Comparison results of samples of 5 kinds of labeled antibody mixtures
[0064]
[0065] The results in Table 1 show that when antibody 1 is labeled alone, more abnormal samples appear; the results in Table 2 show that when antibody 2 is labeled alone, abnormal samples disappear, but the sensitivity of samples below 1 ng / mL is too weak to distinguish clearly. In order to exclude abnormal samples and increase sensitivity at the same time, two antibodies are mixed and labeled. The results in Table 3 show that the correlations of the five serum comparisons are: Comparative Example 3: R 2 =0.6722; Comparative Example 4: R 2 =0.811; Example 1: R 2 =0.9914; Comparative Example 5: R 2 =0.9381; Comparative Example 6: R 2 =0.7689. Affected by non-specific sample numbers 7 and 14: the comparison correlations of Comparative Examples 3, 4, and 6 are not good, and Example 1 is the best.
[0066] Analyzing the test results of Example 1 in Table 3, the X2 / X1 corresponding to the 0.3 ng / mL sample is 0.03, which is used as the critical value for normal and abnormal samples. X2 / X1 less than 0.03 is a normal sample, and greater than 0.03 is an abnormal sample. In order to further confirm that the combined marker can exclude abnormal samples, 200 conventional samples were tested, and the specific data are shown in Table 4. The test results of 200 conventional samples show that X2 / X1 is not greater than 0.03, and no abnormal samples appear, proving that the combined marker is effective.
[0067] Table 4 Comparison results of 200 conventional samples
[0068]
[0069] (2) Long-term stability
[0070] The cTnI assay test strips were prepared according to Example 1, and the whole batch of test strips were assigned values using 16 concentrations of plasma samples with full linear uniform distribution tested by Roche chemiluminescence method as the standard, and fitted into a standard curve.
[0071] This test uses quality control level 1 [2.56 (1.57-3.55) ng / ml] and level 2 [16.07 (10.81-21.33) ng / ml] of self-produced batch number M20210128-1Z as samples, and uses dry fluorescent immunoassay analyzer AFS2000 produced by Guangzhou Lanbo Biotechnology Co., Ltd. to test at 0, 6, 8, 10, 12, 14, and 16 months, respectively. The allowable deviation range is within ±10%, and the specific summary results are shown in Table 5. At the same time, the repeatability of the quality control product was tested. Each sample was tested 10 times each time, and the CV of each month was counted. The allowable CV was within 10%. The specific summary results are shown in Table 6. It can be seen that the CV of quality control 1 in the 16th month exceeded the allowable range.
[0072] Table 5 Changes in quality control over time
[0073]
[0074] Table 6 Changes of quality control repeatability CV over time
[0075]
[0076] Since there are still no recognized external quality assessment samples, accuracy samples or standards for cTnI on the chromatography platform, the accuracy monitoring of cTnI can only be carried out by comparing samples with relatively authoritative methodologies. This experiment still compared samples with Roche cTnI chemiluminescence methodology. The specific comparison results are shown in Table 7. The test results of Roche cTnI kit are used as the horizontal axis and the test results of self-produced cTnI kit are used as the vertical axis. The results in Table 7 are graphically analyzed. See the specific results. Figure 8 .
[0077] Table 7 Results of 100 plasma samples measured by self-produced cTnI kit and Roche cTnI kit
[0078]
[0079] From Table 7 and Figure 8 It can be seen that: Roche's Troponin I Assay Kit (chemiluminescence method) with good performance was selected as the comparison kit, and 100 plasma samples were measured, of which abnormal samples accounted for 37%. The linear regression equation of the two reagents y=0.9646x+0.1376 shows that the a value (0.9646) is close to 1, the b value (0.1376) is close to 0, and R2=0.9956 is close to 1, indicating that the two reagents have a good degree of fit.
[0080] Based on the analysis results of all the above data, it can be seen that the cTnI assay kit can effectively improve the anti-interference ability, test stability, accuracy and precision by mixing different proportions of labeled antibodies, and it is worthy of further promotion and use.
[0081] The above description is only a preferred example of the present invention and does not limit the present invention in any form. Any simple modification, equivalent changes and modifications made to the above embodiments according to the technical essence of the present invention are still within the protection scope of the present invention.
Claims
1. An anti-interference troponin I immunofluorescence test strip, characterized in that: It includes an assembled NC reaction membrane and a binding pad, wherein the NC reaction membrane includes a T line and a C line; the binding pad is coated with a labeled antibody mixture containing two antibodies; The labeled antibody mixture contains the following components in percentage by weight: Sucrose 1% Bovine serum albumin 1% Tween 20 0.5% Isopropyl alcohol 0.5% Sodium azide 0.1% cTnI labeled microsphere antibody 1 0.1% cTnI labeled microsphere antibody 2 0.5%; The solvent of the labeled antibody mixture is: Trisbase buffer with a concentration of 50mM; The T line contains a solution having the following mass percentage: Trehalose 1% Bovine serum albumin 1% Tween 20 0.5% Sodium azide 0.1% cTnI antibody PcAb 1mg / ml; The solvent was phosphate buffer at a concentration of 50 mM; The C line contains a solution having the following mass percentage: Trehalose 1% Bovine serum albumin 1% Tween 20 0.5% Sodium azide 0.1% Sheep anti-mouse polyclonal antibody 0.6 mg / ml; The solvent was 50 mM phosphate buffer; The anti-interference troponin I immunofluorescence test strip is prepared by the following method: Preparation of NC reaction membrane for Troponin I: 1) Weigh the solutions corresponding to the T line and C line as required; The T-line and C-line positions were sprayed with the corresponding solutions and coated onto the NC membrane. After drying for 12 hours, the NC reaction membrane was prepared. 2) Preparation of Troponin I Binding Pad: a) Labeling of antibody 1 and antibody 2: Two 200 nm fluorescent microspheres were activated by EDC and NHS, coupled with cTnI monoclonal antibody 1 and cTnI monoclonal antibody 2, respectively, for 3 h, and blocked with 10% glycocholic acid for 1 h, respectively, to prepare cTnI labeled microsphere antibody 1 and cTnI labeled microsphere antibody 2; b) preparing a labeled antibody mixture, spraying the labeled antibody mixture onto the pretreated binding pad, and drying it for 12 hours to prepare a fluorescent microsphere-labeled cTnI monoclonal antibody binding pad; 3) Assembly: According to the conventional method, the NC reaction membrane, absorbent paper, conjugate pad and sample pad are sequentially overlapped and pasted on the PVC base plate to assemble the cTnI large plate; 4) Card installation: Cut the cTnI plate into 4 mm strips and put them into the reagent card, and pass through the shell press to obtain; The cTnI monoclonal antibody 1 was purchased from Huakui Jinpei cTnI-3E12, with the catalog number M3063; The cTnI monoclonal antibody 2 was purchased from Hytest's Anti-cTnI with a catalog number of 4T21cc MAb560cc.
Citation Information
Patent Citations
Immunofluorescence quantitative test strip for detecting troponin I
CN107942075A
Preparation method of troponin I antibody used for preparing immune diagnostic reagent and obtained strain
CN109912713A
Detection card, kit and detection method for detecting content of hypersensitive cardiac troponin I
CN116539886A
Cardiac troponin I immunochromatography detection card, kit and application thereof
CN118275698A
Cardiac troponin I and cardiac troponin T combined determination test strip and kit as well as preparation method and application of cardiac troponin I and cardiac troponin T combined determination test strip
CN118275699A
